Product nameAnti-Von Willebrand Factor antibody
See all Von Willebrand Factor primary antibodies
DescriptionSheep polyclonal to Von Willebrand Factor
Tested applicationsSuitable for: IHC-Fr, Immunodiffusion, Flow Cyt, ELISA, ICC/IFmore details
Unsuitable for: IHC-P
Species reactivityReacts with: Mouse, Human, Pig
Purified human von Willebrand factor.
General notesThis product should be stored undiluted. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.09% Sodium azide
Constituents: Glycine buffered saline, 0.1% EACA, 0.01% Benzamidine, 0.0292% EDTA
Concentration information loading...
PurityIon Exchange Chromatography
Purification notesPurified IgG was prepared from serum by ion exchange chromatography.
Our Abpromise guarantee covers the use of ab11713 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-Fr||1/50 - 1/100.|
|Flow Cyt||Use at an assay dependent concentration.
ab37385 - Sheep polyclonal IgG, is suitable for use as an isotype control with this antibody.
|ELISA||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
ab11713 at a 1/1000 dilution staining Von Willebrand Factor in mouse blood vessels by Immunohistochemistry (frozen sections) incubated for 16 hours at 4°C. PFA fixed. Permeabilized with 0.1% Triton. Blocked using 20% serum for 1 hour at 19°C. Secondary used at 1/200 polyclonal Donkey anti-sheep conjugated to Alexa Fluor 647 (pink). Counterstain (blue) DAPI.
ab11713 staining Von Willebrand Factor in porcine heart tissue by Immunohistochemistry (Frozen sections).
Tissue was fixed in acetone, permeabilized using 0.3% Triton/PBS, blocked with 10% serum for 30 minutes at 22°C and then incubated with ab11713 at a 1/50 dilution for 16 hours at 4°C. The secondary used was a FITC conjugated donkey anti-sheep polyclonal used at a 1/1000 dilution.
This product has been referenced in:
- Milan M et al. Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation. Cell Death Dis 9:108 (2018). IF . Read more (PubMed: 29371598) »
- Hao Q et al. Procedure for the Isolation of Endothelial Cells from Human Cerebral Arteriovenous Malformation (cAVM) Tissues. Front Cell Neurosci 12:30 (2018). Read more (PubMed: 29467624) »